Project Summary/Abstract
Focal cerebral ischemia (stroke) afflicts nearly 800,000 Americans each year and often results in permanent
cognitive impairment or death. Efforts in developing a cerebroprotective stroke therapy have largely resulted
in disappointment: the only approved pharmacological therapy is hemolytic treatment with tissue plasminogen
activator (tPA; alteplase). In this project, we will further develop our optimized CaMKII inhibitor peptide
tatCN19o as a cerebroprotective stroke treatment through comparative testing within the NINDS Stroke
Preclinical Assessment Network (SPAN). The 30 amino-acid peptide is selective, stable, potent, water
soluble, and has excellent chemistry, manufacturing, and control (CMC) properties. Importantly, tatCN19o
was highly effective in vivo in global cerebral ischemia (GCI) models in both mouse and pig (the latter
unpublished), even at extremely low doses of 0.01-0.02 mg/kg i.v.. The parent compound was also effective
in vivo in a mouse model of acute ischemic stroke (transient middle cerebral artery occlusion; tMCAo).
Neuroprotection was seen even at the latest time points tested so far after the various ischemic/excitotoxic
insults (0.5h after global cerebral ischemia; 1h after stroke model; 6h in neuronal cultures). Here, SPAN will
provide rigorous, unbiased testing of tatCN19o in rodent tMCAo models for direct comparison to other
candidate interventions. Several tMCAo conditions are proposed for consideration by the network:
compatibility with hemolytic tPA treatment (the current standard of care) and efficacy after varied insult
duration. To most appropriately represent clinical populations, we propose parallel testing in adult and older
animals of both sexes.